The forecast for hospital discharges for malignant neoplasm of the uterus in France shows a declining trend from 2024 to 2028, decreasing from 33.4 to 31.9 units per hundred thousand persons. This suggests a gradual reduction in the incidence or improved outpatient management of such cases over this period. The year-on-year decrease is consistent, averaging approximately a 1.5% decline annually from 2024 to 2028.
Future trends to watch for include technological advancements in uterine cancer treatment, early detection strategies, and public health initiatives aimed at reducing risk factors. These may further influence hospital discharge rates positively or could introduce new variables into the forecast. Continuous monitoring of healthcare policies and treatment innovations will be critical to refining these forecasts.
